Nrx Pharmaceuticals, Inc. · NASDAQ:NRXP
Nrx Pharmaceuticals — Investor Presentation (September 2026)
20 slides from Nrx Pharmaceuticals's investor presentation, Sep 14, 2026
Slide 1: HERV Drugs that May Change Humanity
GeNeuro ‘An NRx Company HERV Drugs that May Change Humanity (: Ye) A treatment for ALS AY by 2029 (ff) SEPTEMBER 2026
Slide 2: Forward Looking Statements
GeNeuro ‘An NRx Company FORWARD LOOKING STATEMENTS SS i the meaning of Litigati Reform Act of 1995. - ae i ti ial position, bi strategy, drug discovery ; 9, object d materially and adversely subject te from those set forth in or impl but are not limited to, risks related to our. tition, our ability
Slide 3: What if the worst diseases in humanity are caused by ancient viruses?
WHAT IF THE WORST DISEASES IN HUMANITY ARE CAUSED BY ANCIENT VIRUSES THAT ALREADY LIVE IN OUR DNA? a THE MOCER THREAT " us, Rat TO one Gea >> neurovosieat dy oisonoens 2 Ee WoW a GeNeuro WHAT IF WE HAVE A PATH TO THE CURE? An NRx Company SCIENCE IS REVEALING THE CODE. HUMANITY CAN WRITE THE FUTURE.
Slide 4: The Hidden 8%: From Junk DNA to the Dark Genome
THE HIDDEN 8%: FROM “JUNK DNA” TO THE DARK GENOME A REVOLUTION IN OUR UNDERSTANDING OF HUMAN DNA __| THE OLD DOGMA | THE NEW PARADIGM | ‘FoR DECADES, WE WERE TAUGHT. RECENT RESEARCH REVEALS... 8% of our genetic code That 8% is not empty Iti a vast, functional was considered useless— * al outs debris
Slide 5: Human Endogenous Retroviruses (HERVs)
} HUMAN ENDOGENOUS RETROVIRUSES (HERVs) THE HIDDEN THREAT IN ALL HUMAN DNA HEV ARE A MISSING LNG IN THE CAUSE OF WALOR NEURODEGENERATIVEOSEASES WHAT MAKES UP OUR GENOME? ea Vicente You don't “catch” a HERV infection. HERVS are no longer capable of forming infectious virus particles. : Its the replic
Slide 6: Humans Have Co-opted HERV Proteins
HUMANS HAVE CO-OPTED HERV PROTEINS ————*— HERV CO-OPTION: A KEY TO HUMAN EVOLUTION —*——— 1. FOSSILIZED ANCIENT VIRUSES (~30-20 MYA) __2.CO-OPTION OF HERV SEQUENCES seroma citi mi tlre Me ol a eseaon rego gD sa a. He hae — = PPC \ NE icons oF nu none Wey ELEMENT / “NKONA now known | ANCESTRAL GENOME
Slide 7: HERV Proteins Can Also Have a Dark Side
HERV PROTEINS CAN ALSO HAVE A DARK SIDE ~~ _ THE DARK SIDE OF HERVs: DYSREGULATION IN PATHOLOGY = HERV ACTIVATION IN THE GENOME HERV DYSREGULATION a 7 + + eo ALS co Ms @) PSYCHOSIS CANCER ‘&HERV-K ACTIVATION 2S) & HERV-W DEMYELINATION | ‘& BRAIN DYSFUNCTION ‘B HERV-ORIVEN PATHWAYS. 1. Moar ewan 1. t
Slide 8: HERV K Envelope Protein Is Found in the Brain of People with ALS
HERV K ENVELOPE PROTEIN IS FOUND IN THE BRAIN OF PEOPLE WITH ALS WHAT IS ALS? Arelentlessly progressive disease z 3 of the motor neurons 4( Fo MOTOR NEURON Se Ne DEGENERATION 4 PARALYSIS & i en) RESPIRATORY FAILURE 74) 6,000 Pan i 3-5 YEARS GeNeuro ‘An Nx Company SCIENCE IS REVEALING THE CODE. HUMAN
Slide 9: Evidence that HERV-K Envelope Protein Causes ALS
@ Evidence that HERV-K Envelope Protein Causes ALS and Anti-HERV-K Env Might Prevent Degeneration Amyotrophic Lateral Sclerosis (ALS) HERV-K envelope protein is found in CSF of >75% of ALS patients HERV-K Envelope Protein in CSF >75% of ALS patients have detectable HERV-K envelope protein in CSF HER
Slide 10: Three Ways to Counter a Neurotoxic Protein
THREE WAYS TO COUNTER A NEUROTOXIC PROTEIN Intervene at the DNA, RNA, or protein level REMOVE THE ‘SILENCE e NEUTRALIZE + CLEAR GENE EXPRESSION = > — > NOT CURRENTLY FEASIBLE NOT CURRENTLY FEASIBLE THE ACTIONABLE PATH MABS: A PROVEN PRECISION PLATFORM WHY MABS 7 OF 10 ping High molecular specificity
Slide 11: ALS Development Timeline
© ALS DEVELOPMENT TIMELINE File Fast Track Designation" Gnical tals Designation t t File JANUARY 2028 Breokthrough “Start of Phaso 3 coMpuereD suvy 2027 G ‘Antbody compteren —_StttotPhase fumanizaton snd“ pringdy V2 is ih cevlopmentt manufacture ‘SUBMISSION mae ane cells pocesintatn TARGET pata H JA
Slide 12: Tofersen accelerated approval precedent
1. ALS is a serious condition with a lack of available therapies, and 2. Tofersen had an effect on a surrogate endpoint, NfL, that is reasonably likely to predict clinical benefit. Tofersen was approved for ALS patients with SOD 1 mutation (5% of all ALS) based on a 28 week 108 person trial Day Day
Slide 13: A $25mm Path to a Humanity-Changing Drug in 2029
& A $25mm Path to a Humanity-Changing Drug in 2029 ADVANCED DEVELOPMENT The antibody is fully developed and will be ‘manufactured by July 2027 a PRIOR PATIENT B22, \ EXPERIENCE , HERV-W MAb has already been in 500 patients without toxicity LOW PRECLINICAL BARRIER FOAas ssn /, reduced preclinical tox
Slide 14: Funding Pathway to Drug Approval
i) Funding Pathway to Drug Approval 3) 220 \ foe Ween > Ly bi > WY SEED FUNDING BIOMARKER DEVELOPMENT Casella PHASE 1/2 Trial (2027) NRx Pharmaceuticals ~ Congressionally-Directed Congressionally Directed Reg CF and Initiation of Manufacture Medical Research Program Medical Research Program DOD Fund
Slide 15: GeNeuro Leadership
€ } GeNeuro LEADERSHIP VISIONARY LEADERSHIP. SCIENTIFIC EXCELLENCE, TRANSFORMING LIVES. LEADERSHIP TEAM
Slide 16: GeNeuro Partners
GeNeuro PARTNERS STRONG PARTNERSHIPS. SHARED MISSION. GREATER IMPACT. GeNeuro collaborates with leading organizations and experts to advance innovative research, logic diseases. 1 and improve for patients with NEALS Nett of Een target ALS > 4 Se bar Se shoei ee and Stroke ‘Medical Research Program E
Slide 17: Years of Development in Switzerland and Europe
o 15 YEARS OF DEVELOPMENT IN SWITZERLAND AND EUROPE OVER EU 150MM IN PRIOR INVESTMENT ' GeNeuro USA (an NRx Company) awarded all assets of Geneuro, SA | =] Global Patent Portfolio covering antibodies and diagnostic tests, IP partnership with NIH and French Universities g Temelimab (anti HERV W antib
Slide 18: Clinical-stage targets for HERV-mediated diseases
Oo Clinical-stage targets for HERV-mediated diseases SSS SHE, .HeRv.kinals + oH0Azorre itn at nnn 1 Seep edn + pyc ice | | 2. Psychosis + Panning dscssons with FDA to design a proto concept stuty “+ MS clinical als provide phase | safety exposures 3, Multiple Sclerosis 270 patients / 50 centers in t
Slide 19: GeNeuro Patent Portfolio
@ GeNeuro Patent Portfolio PROTECTING OUR PLATFORM. SECURING OUR FUTURE. (Genero hold global patent estate covering our KEY PATENT FAMILIES rt HER cet cot Cra on te dap ice a a coves ceocpncovensce An ERY K Ene aoa = © Ff mivosrnats Sieaaoense @ Smet ~— Sunascomeone: onic ames cineca eg ee @ vusto7s
Slide 20: A Chance to Change the Future of Humanity by Targeting ALS, MS, and Psychosis
GeNeuro An NRx Company AChance to Change 3 the Future of Humanity by Targeting ALS, MS, and Psychosis Jonathan C. Javitt, MD, MPH | CEO GeNeuro @ ‘SEPTEMBER 2026 ‘An NRx Company
NRX Pharmaceuticals — Investor Presentation (September 2026) on 6ix